Healthcare Industry News: HSMN NewsFeed
News Release - October 5, 2021
Amber Implants VCFix(R) spinal system receives US FDA Breakthrough designationSet to vastly improve treatment of vertebral fractures
HAGUE, Netherlands, Oct. 5, 2021 -- (Healthcare Sales & Marketing Network) -- Amber Implants, an innovative medical technology company developing next generation spinal implants for spinal injuries, today announces its VCFix® spinal system, which aims to improve the treatment of vertebral fractures, has been granted the Breakthrough Device Designation by the US FDA.
The US FDA Breakthrough Device program provides patients more timely access to breakthrough technologies that have the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions. This enables Amber Implants to have direct and interactive communications with the US FDA and priority review. Amber Implants will also have more flexibility with regard to clinical studies, a dedicated team for reviewing the application, and reimbursement through Medicare for 4 years.
Dr. Banafsheh Sajadi, Founder & CEO of Amber Implants, said: "Receiving US FDA Breakthrough Designation is a tremendous recognition that will boost our efforts to bring VCFix® to patients. This development speeds up our timeline significantly, with our First-In-Human clinical trial expected to commence in early 2022 both in Europe and the US, taking us one step closer to improving the quality of life of patients with vertebral fractures."
Yearly, over 1.5 million people suffer from vertebral fractures, which cause the patients severe back pain, limited mobility, and increased rate of mortality in an already vulnerable elderly population. Currently, these injuries are treated with injection of PMMA bone cement into the vertebra, and 65% of the patients are facing different types of side-effects after treatment.
VCFix® spinal system is the first solution to treat vertebral fractures that does not rely on bone cement. Through its 3D-printed perforated structure, VCFix® implant aims to stimulate bone ingrowth as a more natural healing process, while providing better stability and better distribution of loads in the spine. The promise of Amber Implants is to bring an easier, more efficient and safer treatment for a broader type of fractures to the market.
About Amber Implants
Amber Implants is a medical technology company located in the Netherlands and United States. Founded in 2018, the Company has developed the next generation of spinal implants for Vertebral Compression Fractures (VCF), and is focussed on improving patient outcomes through implants that provide more natural healing and stability. Using Additive Manufacturing (AM) and higher precision CNC technologies Amber Implants has developed novel and revolutionary expandable implants used to create unique solutions for spinal and other orthopedic disorders.
VCFix® spinal system is the first cementless solution to treat broad types of vertebral fractures. Through its 3D-printed perforated structure, VCFix® implant aims to stimulate bone ingrowth, providing a more natural healing process. It is optimized for mechanical strength, maximum fracture reduction and anatomical restoration. VCFix® implant provides pedicle anchorage for better stability, better distribution of loads on the middle and posterior columns of the spine and also, possibility for posterior fixation for more unstable fractures. The VCFix® spinal system is provided with a user-friendly single-use sterile surgical kit for perfect traceability and reduced risks of infection. VCFix® will be the new generation and an easier, more efficient and safer treatment for patients with vertebral fractures.
For more information, please contact Info@amberimplants.com
Source: Amber Implants
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.